Guggenheim Downgrades Ra Pharma (RARX) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
- SanDisk upgraded at JPMorgan after investor day; shares climb
Stifel Downgrades Ra Pharma (RARX) to Hold
November 7, 2019 6:43 PM ESTStifel analyst Stephen Willey downgraded Ra Pharma (NASDAQ: RARX) from Buy to Hold.
For an analyst ratings summary and ratings history on Ra Pharma click here. For more ratings news on Ra Pharma click here.
Shares of Ra Pharma closed at $46.90 yesterday.
... More